4 ms·
At this point, what is the cost-benefit of further vaccine development versus heavier investment in drugs and other therapies to reduce the severity of disease?
by nerdponx 6y ago
At this point, what is the cost-benefit of further vaccine development versus heavier investment in drugs and other therapies to reduce the severity of disease?
There are a couple doctors in the US (particularly Peter McCullough) who make a case that we haven't invested enough in the latter and too much in the former. Naturally the anti-vax people seem to love these guys, so it's hard to find any kind of balanced analysis on it.
Or do the numbers still work out to be "more pandemic, more full hospitals, many more dead" no matter how good the drug treatment gets?
- amluto 6y agoThe cost vs benefit analysis is: do all of the above. The total amount spent on biotech related to Covid is negligible compared to the cost of Covid. Israel seems to understand this. Many other countries are orders of magnitude off in their analysis.
- jariel 6y agoThis is true, but this is not Israel's calculation, far from it. They are playing a zero-sum game of outbidding others so that they are 1st, no matter what. Countries like the UK that invested in supply chain efficiencies well ahead of vaccine validation, even as there was risk of the investment failing ... this was acting ahead. Almost every nation failed at this: we should have all been investing 10x what we did in anything to get the vaccines ready, even for those that ultimately failed because the $20B wasted on unneeded prep would have been less than the amount wasted in our current lock downs that could have been avoided were we already to have been vaccinated.
- deleted 6y ago[deleted]
- hannob 6y agoA lot has been invested in drugs. Most of them don't work. The best that was found was Dexamethasone, which reduces mortality in severe cases significantly. Generally medication for viral infections seems to be hard. There isn't much good medication for other respiratory viral diseases. It doesn't look like a major breakthrough in drug treatment will happen. A vaccine can make the difference between "you get the disease" and "you don't get the disease and can't spread it to others". No drug comes remotely close to that.
- amluto 6y agoA lot of very competent coordinated studies of drugs have been done. Oh wait, no it hasn’t. We had a mishmash of variously competent and incompetent studies of AZ/HCQ. We have anecdotal data on ivermectin. We have some preliminary studies of fluvoxamine (excellent results, needs follow up); the large scale expedited follow up is MIA. It’s been over six months from the original study — there is no fundamental reason it should take more than two months to test it on a few tens of thousands of people. Ditto for anti-androgens. Camistat ought to have at least some effect (famous last words); this has been known for something like a year with no meaningful followup. What’s needed here is IMO public health department coordination on studies, which isn’t quite the same thing as money.
- entee 6y agoTo be clear, almost all of these studies showed very small effect sizes. The best therapeutics we have are remdesevir (small but real effect on severity, unclear effect on hospitalization and death), dexamethosone (moderate to large effect on death when hospitalized), and antibody drugs for which Lilly’s has already been remove because ineffective against variants though Regeneron’s cocktail seems quite good. Fluvoxamine is I’m sure under investigation, we’ll get a readout eventually but that’s a relatively new result. The best drugs we have are either: 1.) treat the virus with a novel entity (Regeneron, the other antibodies) 2.) treat the inflammation (dexamethosone, possibly eventually fluvoxamine) The repurposing and general antivirals (including remdesevir) have little effect and likely won’t make a difference. There are novel drugs being developed (Pfizer just started a protease inhibitor trial) but that’s the only place I’d expect to see real impact, with fluvoxamine as a treat the symptoms wildcard. People have been trying to find drugs or repurpose, and academic medical centers have been working on it. It’s that almost nothing works when subjected to the hard trials.
- maxerickson 6y agoThere's likely room to pick better monoclonal antibodies to use. There was an antibody identified that smashed variants, for instance. https://www.medrxiv.org/content/10.1101/2021.01.26.21250224v2 https://www.medrxiv.org/content/10.1101/2021.01.26.21250224v... Some contextualization at https://twitter.com/K_G_Andersen/status/1367592606641704961 https://twitter.com/K_G_Andersen/status/1367592606641704961
- maxerickson 6y agoHow recent are these arguments? Deploying the vaccines is very cheap compared to hospitalization. And like a sibling comment has already said, we should just be spending money anywhere it even seems to make sense.
- nerdponx 6y agoMcCullough recently testified before the Texas state senate: https://youtu.be/QAHi3lX3oGM https://youtu.be/QAHi3lX3oGM He argued that drugs can and do significantly reduce hospitalization. He also claimed that literally nobody was stuffing drugs to reduce hospitalization, which is a strong claim but alarming if true.
- maxerickson 6y agoHis narrative is a bit cartoonish. He complains that communication was silenced starting in May 2020 and is testifying there because of a paper published in August 2020 in one of the most prominent journals in the US. An alternative explanation about the lack of ambulatory care is that most protocols don't really move the needle... I also don't understand why he thinks the vaccine doesn't make sense for people under 50 (he says there is no scientific rationale for it). I'm in my early 40s and have a chance of dying of greater than 1/10,000 if I get infected. The vaccines cost very little and carry much less risk than that!
- nerdponx 6y agoIndeed, this is why I wanted to get some feedback. It definitely seemed exaggerated and I'm not sure what his point was supposed to be by the end of it. I also found it odd that somehow his practice was seeing incredible results with drug combinations in keeping people out of hospitals, but somehow this effect wasn't noticed by any other medical professionals or researchers anywhere else in the world. Are combination protocols really that under-studied?
- kurthr 6y agoThere's lots of work on anti-virals and other drugs, but unless you happen to hit a pre-approved drug showing both efficacy and safety will take so long that it probably won't matter until the next epidemic. Drug treatments are much harder to develop without significant side-effects and also likely less effective than a well targeted vaccine. Watch around 1hr into this TWiV, if you're interested in what targets there are for anti-virals, who's working on them, and why they're hard. https://www.youtube.com/watch?v=7dL-ll8dSmY https://www.youtube.com/watch?v=7dL-ll8dSmY